Potential Drug Targets in the Pentose Phosphate Pathway of Trypanosomatids.
The trypanosomatids, Trypanosoma brucei, Trypanosoma cruzi and Leishmania spp, are causative agents of important human diseases such as African sleeping sickness, Chagas' disease and Leishmaniasis, respectively. The high impact of these diseases on human health and economy worldwide, the unsatisfactory available chemotherapeutic options and the absence of human effective vaccines, strongly justifies the search for new drugs. The pentose phosphate pathway has been proposed to be a viable strategy to defeat several infectious diseases, including those from trypanosomatids, as it includes an oxidative branch, important in the maintenance of cell redox homeostasis, and a non-oxidative branch in which ribose 5-phosphate and erythrose 4-phosphate, precursors of nucleic acids and aromatic amino acids, are produced. This review provides an overview of the available chemotherapeutic options against these diseases and discusses the potential of genetically validated enzymes from the pentose phosphate pathway of trypanosomatids to be explored as potential drug targets.
['Loureiro|Inês|I|', 'Faria|Joana|J|', 'Santarem|Nuno|N|', 'Smith|Terry K|TK|', 'Tavares|Joana|J|', 'Cordeiro-da-Silva|Anabela|A|']
D000981:Antiprotozoal Agents D014355:Chagas Disease D005954:Glucosephosphate Dehydrogenase D006801:Humans D007896:Leishmaniasis D010427:Pentose Phosphate Pathway D015800:Protozoan Proteins D014346:Trypanosoma brucei brucei D014349:Trypanosoma cruzi D014353:Trypanosomiasis, African
drug targets pentose phosphate pathway Trypanosomatids treatment.